Compare TIRX & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIRX | EOLS |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 444.0M |
| IPO Year | 2021 | 2018 |
| Metric | TIRX | EOLS |
|---|---|---|
| Price | $0.66 | $6.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.80 |
| AVG Volume (30 Days) | 138.8K | ★ 1.1M |
| Earning Date | 08-22-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $285,823,000.00 |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $23.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 158.74 | 15.10 |
| 52 Week Low | $0.60 | $5.71 |
| 52 Week High | $6.45 | $17.12 |
| Indicator | TIRX | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 52.83 |
| Support Level | $0.61 | $6.83 |
| Resistance Level | $1.10 | $7.29 |
| Average True Range (ATR) | 0.14 | 0.25 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 13.90 | 68.82 |
Tian Ruixiang Holdings Ltd is an Insurance Brokerage firm. It distributes a wide range of insurance products, which are categorized into two groups; property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and other insurances, such as health insurance, life insurance, and miscellaneous insurances. It also generates a small amount of revenue from risk management services. The firm act on behalf of its customers seeking insurance coverage from insurance companies. It generates revenue from the provision of insurance brokerage services.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.